Last reviewed · How we verify
NCT03609827
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
trial testing Melphalan in Hematologic Malignancies in 25 participants. Completed in 31 May 2021.
31 May 2021
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 September 2015 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Melphalan (melphalan) — full drug profile →
Conditions studied
- Hematologic Malignancies — all drugs for Hematologic Malignancies →
- Nonmalignant Diseases — all drugs for Nonmalignant Diseases →
- Immunodeficiencies — all drugs for Immunodeficiencies →
- Hemoglobinopathies — all drugs for Hemoglobinopathies →
Sponsor
University of California, San Francisco
Who can join
Under 17, any sex, with Hematologic Malignancies or Nonmalignant Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and individual factors cause changes in melphalan drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03609827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Melphalan
Trials testing the same drug.
- NCT06954987 — Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell · Phase 2 · not yet recruiting
- NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
- NCT07228624 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas · Phase 2 · recruiting
- NCT06287944 — 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiati · Phase 1 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
Other recruiting trials for Hematologic Malignancies
Currently open trials in the same condition.
- NCT04546945 — Aberrant Expression of CD56 in Patients With Hematologic Malignancies. · recruiting
- NCT06926595 — Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention · Phase 2 · recruiting
- NCT07186192 — Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy · Phase 3 · recruiting
- NCT07195916 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies · Phase 1 · recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03609827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 4 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03609827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing